

BioPorto

2025 Preliminary figures, Guidance 2026 and Business Update

Carsten Buhl, CEO & Niels Høy Nielsen, CFO

February 6, 2026

Forward-looking statements

References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matter contained herein. By viewing or receiving or reading this presentation or attending any meeting where this presentation is made, you agree to be bound by the limitations, qualifications and restrictions set out below.

This presentation contains forward-looking statements. Words such as “believe”, “expect”, “may”, “plan”, “strategy”, “estimate”, “target” and similar expressions identify such forward-looking statements. Statements other than historical facts included in this presentation concerning our plans, objectives, goals, future events and performance are forward-looking statements. They involve risks, uncertainties and other factors, which may cause actual results, performance and achievements to differ materially from the results discussed in the forward-looking statements. These include numerous assumptions, risks and uncertainties, many of which are beyond BioPorto’s control. These risks and uncertainties are described from time to time in BioPorto’s Announcements and in its 2024 Annual Report under Risk Factors. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date of this presentation.

This presentation is for information purposes only and does not constitute an offer to sell or a solicitation of any offer to buy any securities issued by the Company in any jurisdiction. The information contained herein is not for distribution in the United States of America. This document does not constitute, or form part of, an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. The Company’s securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and may not be offered or sold within the United States absent registration or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to offer or solicit an offer to buy any securities in the Company in the United States or to make a public offering of the securities in the United States. Company securities may be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) in reliance on Rule 144A.



Invest in AKI Diagnostic - Invest in BioPorto



Early detection of AKI (Acute Kidney Injury) represents a **major unmet need**¹



BioPorto's ProNephro AKI™ (NGAL) is **the first FDA-cleared test for pediatric AKI assessment**



Defined pathway for **FDA approval** and **commercial launch** of ProNephro AKI (NGAL) for **adults in US** to **open addressable market**



Significant market potential – Total targeted ICU (Intensive Care Unit) Market estimated at app. USD 700m²



Growth Case based on an asset light business model with high margins and clear value drivers towards 2028



1. NephroCheck at 10: addressing unmet needs in AKI diagnosis and risk stratification | Clinical Kidney Journal | Oxford Academic 2. Source: Management estimates | S2N Data, BIS data | US Ped Risk Strat indication is for 3 months through 21yoa

Highlights for the fourth quarter of 2025



A commercial milestone in the fourth quarter of 2025 was the availability of **ProNephro™ AKI (NGAL) for the US market.**



The “**Forward**” **Strategic Plan** was established in November. This is a three-year plan focusing on building market adoption, capturing high growth and expanding the addressable market, including **new aspirations towards 2028.**




In November, BioPorto executed on its **Financing Strategy** with a pre-subscribed private placement of approximately DKK 43 million with existing shareholders and **new institutional** and private investors.



The "Forward" Strategic Plan


Focus on Execution of **Market Access & Commercialization** to transform kidney care





+60 Hospitals by end of 2026 – Creating Adoption

Expected Development of # of US Hospitals from 2024-2026




- Creating **awareness** and **understanding**; to create the future demand
- **NGAL Research Use Only (RUO)** & continued focus on the Pediatric segment
- Focus on the market in North America; initiating multiple **new processes**
- Support the released product for the Roche instrument Cobas 501 **for Pediatric segment**



Clinical validation study for adults – Creating Access

Defined pathway






Continued NGAL growth in 2025 vs 2024 (Preliminary and unaudited)

Revenue Q4 2025 vs Q4 2024, DKKm

Revenue per quarter, DKKm

FY 2025 vs 2024



FY 2025 vs 2024

Total revenue
DKK 40.3m +11% (+13%)

Total NGAL revenue
DKK 28.2m +22% (+25%)

US NGAL **+25% (+29%)**
 ROW NGAL **-34%**
 ProNephro AKI™ **+4.3m**


Adjusted EBITDA loss
App. DKK 77m +8%

() Growth at Constant Exchange Rates



NGAL Sales US continuing strong growth (Preliminary)

US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates)





Financial Guidance 2026

Total NGAL Revenue



DKK 33-42m
(20-50%)

Total Revenue



DKK 48-58m
(20-45%)

Adjusted EBITDA loss



DKK 50-60m



Q&A